Home | All trials

[RDF data]
Trial NCT00000342

Resource URI: http://static.linkedct.org/resource/trials/NCT00000342
PropertyValue
linkedct:brief_title Risperidone for the Treatment of Cocaine Dependence - 7
linkedct:condition <http://static.linkedct.org/resource/condition/2992>
linkedct:criteria Inclusion Criteria: M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent. Exclusion Criteria: Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 50 Years
linkedct:eligibility_minimum_age 21 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date September 20, 1999
linkedct:id NCT00000342
rdfs:label Trial NCT00000342
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Institute on Drug Abuse (NIDA)
linkedct:location <http://static.linkedct.org/resource/location/209856>
linkedct:nct_id NCT00000342
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Risperidone for the Treatment of Cocaine Dependence
linkedct:org_study_id NIDA-3-0010-7
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/60742>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000342>
linkedct:phase Phase 2
linkedct:secondary_id Y01-3-0010-7
linkedct:source National Institute on Drug Abuse (NIDA)
linkedct:start_date July 1996
linkedct:study_design Treatment, Double-Blind, Placebo Control, Parallel Assignment
linkedct:study_type Interventional
linkedct:summary The purpose of this study is to evaluate clinical safety and pharmacological efficacy in the treatment of cocaine dependence, to evaluate impact of treatment on craving, and to correlate evidence of baseline neurotoxic damage of cocaine with treatment outcome and clinical side-effects.
rdf:type linkedct:trials
linkedct:verification_date June 1997